IP Library Granted Patent US 10,174,362
Granted Patent B2
US 10,174,362 · App. 15/872,791 · Granted Jan 8, 2019

Nucleic acid preservation solution and methods of manufacture and use

Inventor: Federico Carlos Arejola Gaeta (Torre Molinos, ES)
Assignee: Spectrum Solutions L.L.C.
C12Q1/6806C12N15/1003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,174,362
App. No.
15/872,791
Granted
Jan 8, 2019
Kind
B2
Abstract

Disclosed is nucleic acid preserving compositions and methods of manufacturing and using the same. Compositions include a carrier, a chaotropic agent, a buffering agent, a chelating agent, a surfactant, an alcohol, an acid, and a mucolytic agent. Compositions as aqueous solutions can include water as a carrier. Preferred embodiments include water, guanidine thiocyanate, Tris, EDTA, SLS, SDA 3C, HCl, and N-acetyl-L-cysteine. Some embodiments include a colored dye as a visual indicator. Methods of manufacturing include combining the components into a mixture, such as an aqueous solution. Methods of use include providing a biological sample that includes nucleic acid and contacting the biological sample with the composition. Kits include the composition disposed in a portion of a biological sample collection apparatus.

Claims (83)

1. A human nucleic acid preservation composition, comprising:

39.53%-48.31% guanidine thiocyanate, w/w;

2.39%-2.92% tris(hydroxymethyl)aminomethane (Tris), w/w;

0.73%-0.89% ethylenediaminetetraacetic acid (EDTA) or EDTA disodium (salt) dihydrate, w/w;

0.251%-0.307% sodium lauroyl sarcosinate (SLS), w/w;

15.96%-19.50% alcohol, w/w, the alcohol comprising ethanol;

0.084%-0.102% N-acetyl-L-cysteine (NAC), w/w;

hydrochloric acid qs to pH 7.5-8.5; and

an aqueous carrier comprising filtered, purified, distilled, and/or deionized water.

2. The composition of claim 1 further comprising a dye or coloring agent.

3. The composition of claim 1 , wherein the composition comprises:

43.48%-44.36%, w/w, of the guanidine thiocyanate;

2.62%-2.68%, w/w, of the Tris;

0.80%-0.82%, w/w, of the EDTA or EDTA disodium (salt) dihydrate;

0.276%-0.282%, w/w, of the SLS;

17.55%-17.91%, w/w, of the alcohol;

0.092%-0.094%, w/w, of the NAC; and

the hydrochloric acid qs to pH 7.8-8.2.

4. The composition of claim 1 , wherein the composition is substantially free or devoid of mucolytic agent(s) and/or reducing agent(s) other than N-acetyl-L-cysteine.

5. The composition of claim 1 , wherein the composition comprises:

41.72%-46.12%, w/w, of the guanidine thiocyanate;

2.52%-2.78%, w/w, of the Tris;

0.77%-0.85%, w/w, of the EDTA or EDTA disodium (salt) dihydrate;

0.265%-0.293%, w/w, of the SLS;

16.84%-18.62%, w/w, of the alcohol;

0.088%-0.098%, w/w, of the NAC; and

The acid qs to pH 7.6-8.4.

6. The composition of claim 1 , wherein the composition is substantially free or devoid of antimicrobial agent(s), bactericidal agent(s), and/or bacteriostatic agent(s) other than the guanidine thiocyanate, SLS, alcohol, and NAC.

7. The composition of claim 1 , wherein the composition is substantially free or devoid of inhibitor(s) of ribonuclease other than the guanidine thiocyanate, SLS, alcohol, and NAC.

8. The composition of claim 1 , wherein the composition is substantially free or devoid of protease(s).

9. The composition of claim 1 , wherein the alcohol comprises a mixture of about 95% ethanol, v/v, and about 5% isopropanol, v/v.

10. A nucleic acid preservation composition, comprising:

a carrier;

20-50%, w/w, of a chaotropic agent;

1-5%, w/w, of a buffering agent;

0.05-2.5%, w/w, of a chelating agent;

0.05-2.5%, w/w, of a surfactant;

5-25%, w/w, of alcohol;

an acid qs to pH 7.2-8.8; and

0.005-0.25%, w/w, of a mucolytic agent.

11. The composition of claim 10 , wherein the composition comprises:

39.53%-48.31%, w/w, of the chaotropic agent;

2.39%-2.92%, w/w, of the buffering agent;

0.73%-0.89%, w/w, of the chelating agent;

0.251%-0.307%, w/w, of the surfactant;

15.96%-19.50%, w/w, of the alcohol;

0.084%-0.102%, w/w, of the mucolytic agent; and

the acid qs to pH 7.5-8.5%.

12. The composition of claim 11 , wherein the composition is substantially free or devoid of antimicrobial agent(s), bactericidal agent(s), and/or bacteriostatic agent(s) other than the chaotropic agent, the surfactant, the alcohol, and the mucolytic agent.

13. The composition of claim 11 , wherein the composition is substantially free or devoid of inhibitor(s) of ribonuclease other than the chaotropic agent, the surfactant, the alcohol, and the mucolytic agent.

14. The composition of claim 11 , wherein the composition is substantially free or devoid of protease(s).

15. The composition of claim 10 , wherein the composition comprises:

43.48%-44.36%, w/w, of the chaotropic agent;

2.62%-2.68%, w/w, of the buffering agent;

0.80%-0.82%, w/w, of the chelating agent;

0.276%-0.282%, w/w, of the surfactant;

17.55%-17.91%, w/w, of the alcohol;

0.092%-0.094%, w/w, of the mucolytic agent; and

the acid qs to pH 7.8-8.2.

16. The composition of claim 15 , wherein the composition is substantially free or devoid of antimicrobial agent(s), bactericidal agent(s), and/or bacteriostatic agent(s) other than the chaotropic agent, the surfactant, the alcohol, and the mucolytic agent.

17. The composition of claim 15 , wherein the composition is substantially free or devoid of inhibitor(s) of ribonuclease other than the chaotropic agent, the surfactant, the alcohol, and the mucolytic agent.

18. The composition of claim 15 , wherein the composition is substantially free or devoid of protease(s).

19. The composition of claim 10 , wherein:

The carrier comprises filtered, purified, distilled, and/or deionized water;

the chaotropic agent comprises guanidine thiocyanate;

the buffering agent comprises tris(hydroxymethyl)aminomethane (Tris);

the chelating agent comprises ethylenediaminetetraacetic acid (EDTA)

the surfactant comprises sodium lauroyl sarcosinate (SLS);

the alcohol comprises the acid comprises hydrochloric acid (HCl); and

the mucolytic agent comprises N-Acetyl-L-cysteine (NAC).

20. The composition of claim 10 , furthering comprising a dye or coloring agent.

21. The composition of claim 10 , wherein the composition is substantially free or devoid of mucolytic agent(s) and/or reducing agent(s) other than N-acetyl-L-cysteine.

22. The composition of claim 10 , wherein the composition comprises:

41.72%-46.12%, w/w, of the chaotropic agent;

2.52%-2.78%, w/w, of the buffering agent;

0.77%-0.85%, w/w, of the chelating agent;

0.265%4293%, w/w, of the surfactant;

16.84%-18.62%, w/w, of the alcohol;

0.088%-0.098%, w/w, of the mucolytic agent; and

The acid qs to pH 7.6-8.4.

23. The composition of claim 10 , wherein the composition is substantially free or devoid of antimicrobial agent(s), bactericidal agent(s), and/or bacteriostatic agent(s) other than the chaotropic agent, the surfactant, the alcohol, and the mucolytic agent.

24. The composition of claim 10 , wherein the composition is substantially free or devoid of inhibitor(s) of ribonuclease other than the chaotropic agent, the surfactant, the alcohol, and the mucolytic agent.

25. The composition of claim 10 , wherein the composition is substantially free or devoid of protease(s).

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Mar 11, 2021
From: JPMORGAN CAHSE BANK, N.A.
To: SPECTRUM SOLUTIONS L.L.C.
Reel/Frame 055565/0282 →
SECURITY INTEREST Recorded Mar 5, 2021
From: SPECTRUM SOLUTIONS L.L.C.
To: TWIN BROOK CAPITAL PARTNERS, LLC, AS AGENT
Reel/Frame 055503/0673 →
SECURITY INTEREST Recorded May 20, 2019
From: SPECTRUM SOLUTIONS L.L.C.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 049235/0813 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2018
From: GAETA, FEDERICO CARLOS AREJOLA
To: SPECTRUM SOLUTIONS L.L.C.
Reel/Frame 044631/0440 →
Continuity (2)
Provisional Application 62446818 · Jan 16, 2017
Related Publication 20180201977A1 · Jul 19, 2018
Cited By (1)
US 12,221,632